Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bossuyt

Showing results (51-60 of 134) with videos related to

Pageof 14
Sort By:
The Lancet. Gastroenterology & Hepatology|May 10, 2018
Diffusion-weighted MRI in inflammatory bowel diseaseLieven Pouillon, Valérie Laurent, Marc Pouillon, et al.
Gut|January 10, 2020
Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red densityPeter Bossuyt, Hiroshi Nakase, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|November 10, 2025
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's DiseaseSuzanne I Anjie, Geert R D'Haens, Filip Baert, et al.
Inflammatory Bowel Diseases|June 20, 2018
Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART CohortPeter Bossuyt, Filip Baert, Francois D'Heygere, et al.
Journal of Clinical Gastroenterology|February 20, 2026
Development of an Evidence-based Quality Indicator Set for Patients With Inflammatory Bowel Disease in BelgiumLiselotte Fierens, Claire Liefferinckx, João Sabino, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk ModelPeter Bossuyt, Celine Debeuckelaere, Marc Ferrante, et al.
Inflammatory Bowel Diseases|April 19, 2018
Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort StudySaartje Van de Vondel, Filip Baert, Christine Reenaers, et al.
Journal of Crohn'S & Colitis|November 27, 2024
Development of an Automated Tool for the Estimation of Histological Remission in Ulcerative Colitis Using Single-Wavelength Endoscopy TechnologyPieter Sinonquel, Matthias Lenfant, Tom Eelbode, et al.
Journal of Crohn'S & Colitis|June 10, 2025
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 studyMiguel Regueiro, Monika Fischer, Peter Bossuyt, et al.
Acta Clinica Belgica|October 31, 2019
Molecular detection of <i>Helicobacter pylori</i> and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE <i>Helicobacter pylori</i> assayBea Van den Poel, Sarah Gils, Isabel Micalessi, et al.
Pageof 14

Showing results (51-60 of 134) with videos related to

Sort By:
Pageof 14
The Lancet. Gastroenterology & Hepatology|May 10, 2018
Diffusion-weighted MRI in inflammatory bowel diseaseLieven Pouillon, Valérie Laurent, Marc Pouillon, et al.
Gut|January 10, 2020
Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red densityPeter Bossuyt, Hiroshi Nakase, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|November 10, 2025
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's DiseaseSuzanne I Anjie, Geert R D'Haens, Filip Baert, et al.
Inflammatory Bowel Diseases|June 20, 2018
Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART CohortPeter Bossuyt, Filip Baert, Francois D'Heygere, et al.
Journal of Clinical Gastroenterology|February 20, 2026
Development of an Evidence-based Quality Indicator Set for Patients With Inflammatory Bowel Disease in BelgiumLiselotte Fierens, Claire Liefferinckx, João Sabino, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk ModelPeter Bossuyt, Celine Debeuckelaere, Marc Ferrante, et al.
Inflammatory Bowel Diseases|April 19, 2018
Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort StudySaartje Van de Vondel, Filip Baert, Christine Reenaers, et al.
Journal of Crohn'S & Colitis|November 27, 2024
Development of an Automated Tool for the Estimation of Histological Remission in Ulcerative Colitis Using Single-Wavelength Endoscopy TechnologyPieter Sinonquel, Matthias Lenfant, Tom Eelbode, et al.
Journal of Crohn'S & Colitis|June 10, 2025
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 studyMiguel Regueiro, Monika Fischer, Peter Bossuyt, et al.
Acta Clinica Belgica|October 31, 2019
Molecular detection of <i>Helicobacter pylori</i> and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE <i>Helicobacter pylori</i> assayBea Van den Poel, Sarah Gils, Isabel Micalessi, et al.
Pageof 14